What question did this study set out to answer?

To evaluate the real-world efficacy and safety of ruxolitinib in patients with steroid-refractory graft-versus-host disease (GVHD).

March 12, 2026Open Access

Real-World Outcomes of Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease: A Multicenter Retrospective Observational Study from Turkey

Key Points

To evaluate the real-world efficacy and safety of ruxolitinib in patients with steroid-refractory graft-versus-host disease (GVHD).
Conducted a retrospective, multicenter analysis in Turkey
Included adult patients treated with ruxolitinib for moderate-to-severe acute or chronic GVHD
Recorded clinical characteristics, treatment responses, and adverse events
Overall response rate was 90% among 80 patients
1-year overall survival rate was 91.3% and 2-year rate was 82.5%
Severe cGVHD and lack of response to ruxolitinib were associated with reduced survival
Adverse events included infections in 50% of patients and cytopenias in 28.7%.

Abstract

Introduction 60 males), 39 had aGVHD, 68 cGVHD, and 15 oGVHD. The ORR was 72 of 80 patients (90.0%) (complete response: 37 of 80 46.3%, partial response: 35 of 80 43.8%). The 1-year and 2-year OS rates were 91.3% and 82.5%. Severe cGVHD (p < 0.001) and lack of response to ruxolitinib (p = 0.018) were associated with reduced OS. Adverse events included infections in 40 of 80 patients (50.0%), cytopenias in 23 of 80 (28.7%), and cytomegalovirus reactivation in 20 of 80 (25.0%). Conclusion: In this retrospective multicenter cohort, ruxolitinib was associated with high response rates in steroid-refractory GVHD, while disease severity remained a key determinant of survival, and findings should be interpreted as exploratory.

Bookmark

View Full Paper

Cite This Study

Bakırtaş et al. (Mon,) studied this question.

synapsesocial.com/papers/69b2575e96eeacc4fcec5f4e https://doi.org/https://doi.org/10.3390/jcm15052088

Bookmark

View Full Paper